EGFR and non-small cell lung carcinoma: Kimura et al. reported an SMI < 41 cm2/m2 for men and <38 cm2/m2 for women as prognostic in a Japanese advanced NSCLC cohort (88.1% stage IV) receiving chemotherapy or EGFR-tyrosine kinase inhibitors (TKI), yielding 38.3% sarcopenic patients [26].